• PNS135 ARE THE SALES FORECAST FOR MEDICAL DEVICES ACCURATE? A RETROSPECTIVE ANALYSIS IN FRANCE (2018-2019)

    Nov 1, 2019, 00:00

  • PMU9 HIGH DRUG PRICES AND THE ADEQUACY OF RETURN ON PUBLIC INVESTMENT INTO DRUG RESEARCH AND DEVELOPMENT BY THE U.S. NATIONAL INSTITUTES OF HEALTH (NIH).

    Nov 1, 2019, 00:00

  • Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England

    Nov 1, 2019, 00:00

  • PCN520 CLINICAL AND ECONOMIC EVALUATIONS OF MULTIPLE MYELOMA PATIENTS

    Nov 1, 2019, 00:00

  • PDB111 EMPAGLIFLOZIN INDUCED PANCREATITIS: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PMU149 DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CANCER PATIENTS: DID THEY INCREASE IN RECENT YEARS?

    Nov 1, 2019, 00:00

  • PCN69 THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT TARGET DRUGS FOR SECOND-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN RUSSIA

    Nov 1, 2019, 00:00

  • PMU47 ORPHAN DRUG DESIGNATION: NO IMPACT ON PR PROCESS TIMING IN ITALY

    Nov 1, 2019, 00:00

  • PNS89 CATEGORIZATION AND ASSOCIATION ANALYSIS OF RISK FACTORS FOR SAFE DRUG DISPOSAL

    Nov 1, 2019, 00:00

  • PRS24 COST EFFECTIVENESS OF BENRALIZUMAB FOR SEVERE, UNCONTROLLED ORAL CORTICOSTEROID-DEPENDENT ASTHMA IN SWEDEDN

    Nov 1, 2019, 00:00

  • PIN108 THE BURDEN OF EBOLA VIRUS DISEASE (EVD) IN AFRICA: NEED FOR VACCINE (A TARGETED LITERATURE REVIEW)

    Nov 1, 2019, 00:00

  • PCN97 DIRECT COSTS ASSOCIATED WITH NEUTROPENIA AND FEBRILE NEUTROPENIA AS ADVERSE EVENTS OF CHEMOTHERAPY IN SERBIAN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PNS357 HOW TO RESOLVE ISSUES EXPERIENCED BY PAYERS FOR THEIR INVOLVEMENT AT PRE-LAUNCH STAGE

    Nov 1, 2019, 00:00

  • PNS243 TRENDS IN DECISIONS BY THE SCOTTISH MEDICINES CONSORTIUM OVER THE PAST 10 YEARS - AN ANALYSIS OF KEY FACTORS DRIVING ACCEPTANCE

    Nov 1, 2019, 00:00

  • PMS69 EFFECT OF HIP FLEXION CONTRACTURE ON TERMINAL STANCE OF GAIT AMONG INACTIVE UNIVERSITY STUDENTS

    Nov 1, 2019, 00:00

  • PCN314 POPULATION BASED STUDY OF BASELINE BONE DENSITY SCREENING IN PROSTATE CANCER PATIENTS TREATED WITH LONG-TERM ANDROGEN DEPRIVATION THERAPY

    Nov 1, 2019, 00:00

  • PMH62 IMPROVEMENT IN FUNCTIONING, DEPRESSIVE AND COGNITIVE SYMPTOMS AFTER TREATMENT OF MAJOR DEPRESSION WITH VORTIOXETINE. INTERIM RESULTS FROM THE "REAL-LIFE EFFECTIVENESS OF VORTIOXETINE (RELIEVE)” STUDY

    Nov 1, 2019, 00:00

  • PNS267 MODELLING OF LIFECYCLE PRICING IN HTA: METHODOLOGICAL CONSIDERATIONS

    Nov 1, 2019, 00:00

  • Alternative Medicine Process of Care

    Nov 1, 2019, 00:00

  • Medical Devices - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PND104 DIAGNOSIS AND TREATMENT PATTERNS ON BRAZILIAN PATIENTS: RESULTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PND92 TREATMENT PATTERNS AND CHARACTERIZATION OF MIGRAINE PATIENTS FOLLOWED IN HEADACHE SPECIALIZED CENTERS OF PORTUGAL

    Nov 1, 2019, 00:00

  • PCN209 END-OF-LIFE COST FOR LUNG CANCER PATIENTS IN GREECE: A HOSPITAL-BASED RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PNS362 EQ-5D-5L DATA FOR BULGARIAN POPULATION

    Nov 1, 2019, 00:00

  • PRS15 COMPARISON OF HOSPITALIZATION RATES AND LIMITATION OF DAILY ACTIVITIES IN SEVERE ASTHMA PATIENTS RECEIVING BIOLOGIC AND NON-BIOLOGIC TREATMENT REGIMENS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PGI6 TREATMENT FAILURE AND REMISSION IN MODERATE TO SEVERE ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD) IN EUROPE

    Nov 1, 2019, 00:00

  • PIH50 MODERN APPROACH TO CREATION OF DONOR BREAST MILK BANKS IN UKRAINE

    Nov 1, 2019, 00:00

  • PGI52 INTERNATIONAL ADAPTATION AND LINGUISTIC VALIDATION OF NASH-CHECK, A NOVEL PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS

    Nov 1, 2019, 00:00

  • PCN498 REAL-WORLD EVIDENCE ON THE UTILISATION OF ABIRATERONE AND ENZALUTAMIDE IN IRELAND

    Nov 1, 2019, 00:00

  • PCN240 POTENTIAL BUDGET IMPACT OF ADJUVANT TREATMENTS FOR STAGE III MELANOMA IN IRELAND

    Nov 1, 2019, 00:00

  • Surgery - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN528 ASSOCIATION OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS WITH LUNG CANCER AMONG A U.S. COHORT: A REAL WORLD APPROACH

    Nov 1, 2019, 00:00

  • PBI52 ATMPS IN EUROPE: EXISTING CHALLENGES AND FUTURE DIRECTIONS

    Nov 1, 2019, 00:00

  • PCN387 ARE NICE APPRAISAL COMMITTEES BEING CONSISTENT IN THEIR IMPLEMENTATION OF THE END OF LIFE CRITERION?

    Nov 1, 2019, 00:00

  • PMD50 COMPARING THE ABILITY OF TWO INNOVATIVE OSTOMY BAGS TO PREVENT BALLOONING IN A REAL-LIFE SETTING

    Nov 1, 2019, 00:00

  • PND52 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

    Nov 1, 2019, 00:00

  • PMU63 FRENCH HEALTH TECHNOLOGY ASSESSMENT OF DRUGS APPROVED UNDER EXCEPTIONAL CIRCUMSTANCES

    Nov 1, 2019, 00:00

  • PNS146 WHAT APPROACH SHOULD BE TAKEN IN ORDER TO EFFECTIVELY MANAGE BEHAVIORAL HEALTH RISK FACTORS? A CONSENSUS PANEL ANALYSIS FOR GREECE

    Nov 1, 2019, 00:00

  • PCV116 USING ADMINISTRATIVE CLAIMS DATA TO ESTIMATE THERAPEUTIC INTENSITY IN MEDICALLY MANAGED HEART FAILURE PATIENTS

    Nov 1, 2019, 00:00

  • NO Specific Disease - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN286 HEALTH TECHNOLOGY ASSESSMENT DECISIONS OVER THE LAST DECADE IN THE UNITED KINGDOM AND THE NETHERLANDS - A FOCUS ON NON-SMALL-CELL LUNG CANCER

    Nov 1, 2019, 00:00

  • PIN84 KNOWLEDGE, ATTITUDE AND PRACTICES ABOUT ZIKA VIRUS AMONG PHARMACY STUDENTS IN MAINLAND UNITED STATES (US) AND NON-MAINLAND US (PUERTO RICO AND WEST INDIES

    Nov 1, 2019, 00:00

  • PCN155 AN ECONOMIC SYSTEMATIC LITERATURE REVIEW FOR UNTREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PRS29 COMPARATIVE PHARMACOECONOMICS OF BX IN THE TREATMENT OF PATIENTS WITH UNCONTROLLED MODERATE AND SEVERE ATOPIC ASTHMA IN THE RUSSIAN HEALTH CARE SETTING

    Nov 1, 2019, 00:00

  • PNS300 HOW TO INTERPRET AND ACCOUNT FOR OVER/UNDER-DISPERSION WHEN MODELLING INCIDENCE RATES WITH POISSON MODELS

    Nov 1, 2019, 00:00

  • PNS313 A SYSTEMATIC REVIEW OF PATIENT EXPERIENCE DATA CAPTURED IN CLINICAL TRIALS

    Nov 1, 2019, 00:00

  • PBI23 A COST ANALYSIS OF HEMOSTATIC SURGICAL RESOURCES ASSOCIATED WITH A NOVEL FIBRIN SEALANT COMPARED TO STANDARD OF CARE ACROSS SURGERY TYPES

    Nov 1, 2019, 00:00

  • PMU97 A REVIEW OF CONTRIBUTIONS MADE BY PATIENT ADVOCACY GROUPS IN THE ASSESSMENT OF DRUGS BY THE FRENCH HAUTE AUTORITE DE SANTE

    Nov 1, 2019, 00:00

  • PDG17 HOSPITAL COSTS ASSOCIATED WITH THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE IN HUNGARY

    Nov 1, 2019, 00:00

  • PCN316 TREATMENT PATTERNS OF ADVANCED SOFT-TISSUE SARCOMA IN ARGENTINA

    Nov 1, 2019, 00:00

  • PNS253 IS THERE STILL A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS? UPDATED ANALYSIS

    Nov 1, 2019, 00:00

  • PRO89 TOO ULTRA-RARE FOR CARE? ORPHAN DRUG AVAILABILITY FOR RESPIRATORY DISEASES: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN346 MEAN VERSUS MEDIAN: WHAT DOES NICE CONSIDER TO BE THE MOST APPROPRIATE STATISTIC FOR ESTIMATING SHORT LIFE EXPECTANCY TO SATISFY END-OF-LIFE CRITERIA?

    Nov 1, 2019, 00:00

  • PMH37 COMPARING THE QUALITY OF SLEEP AMONGST BENZODIAZEPINE DEPRESCRIBED GROUP AND CONTINUING GROUP

    Nov 1, 2019, 00:00

  • PCN463 EUROQOL-5D ASSESSED HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS VS. GENERAL POPULATION IN BULGARIA

    Nov 1, 2019, 00:00

  • PIN19 ECONOMIC EVALUATION OF THE FIRST PILOT OF PARTIAL DECENTRALIZATION OF HIV CARE AND TREATMENT FOR MEN WHO HAVE SEX WITH MEN IN GUATEMALA CITY FROM THE PATIENT'S PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCV30 COST-EFFECTIVENESS OF NOACS IN PATIENTS WITH ATRIAL FIBRILLATION: USING REAL-WORLD DATA FOR EXTERNAL VALIDATION

    Nov 1, 2019, 00:00

  • PNS43 ORGANISING THE LITERATURE IN A SYSTEMATIC LITERATURE REVIEW USING FACTOR ANALYSIS

    Nov 1, 2019, 00:00

  • PMU114 SPECIALISED HEALTH TECHNOLOGY ASSESSMENT PROCESSES FOR VERY RARE DISEASES: PAST, PRESENT AND FUTURE

    Nov 1, 2019, 00:00

  • PNS280 AN ASSESSMENT OF THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS WITHOUT A PATIENT ACCESS SCHEME OF COMMERCIAL ACCESS AGREEMENT

    Nov 1, 2019, 00:00

  • PCN321 IMAGING SURVEILLANCE OF PATIENTS WITH OVARIAN CANCER AFTER SUCCEEDING EARLY TREATMENT: A CROSS-SECTIONAL ANALYSIS FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PRO82 REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN

    Nov 1, 2019, 00:00

  • PGI20 MULTIMATRIX VERSUS TIME-DEPENDENT DELIVERY OF MESALAZINE FOR ULCERATIVE COLITIS THERAPY IN KAZAKHSTAN: A HEALTH ECONOMIC EVALUATION

    Nov 1, 2019, 00:00

  • PNS413 DEVELOPMENT, VALIDATION AND CONCORDANCE OF CLINICAL CODE SETS USED IN REAL-WORLD DATABASE STUDIES

    Nov 1, 2019, 00:00

  • PDB130 ECONOMIC BURDEN OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR THERAPIES: ANALYSIS OF NATIONAL SPECIALTY PHARMACY DATABASE

    Nov 1, 2019, 00:00

  • PIH55 A MULTIVARIATE APPROACH TO EXPLORE THE DRIVERS OF MEDICINE ACCEPTABILITY IN PEDIATRICS

    Nov 1, 2019, 00:00

  • PGI60 IDENTIFYING PROGRESSING PATIENTS IN AN ARTIFICIAL INTELLIGENCE (AI) BASED COHORT OF NONALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN512 PROGRESSION, OVERALL SURVIVAL, AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY: A SWEDISH REGISTER-BASED STUDY

    Nov 1, 2019, 00:00

  • PBI15 ECONOMIC BURDEN OF SICKLE CELL DISEASE: A TARGETED GLOBAL LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PRO81 EVOLVING COMMERCIALISATION OPPORTUNITIES IN RARE DISEASES OUTSIDE EUROPE

    Nov 1, 2019, 00:00

  • PRO142 PSYCHOMETRIC PERFORMANCE OF THE INDOLENT SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ISM-SAF)

    Nov 1, 2019, 00:00

  • PCN361 A MULTICRITERIA DECISION ANALYSIS (MCDA) TO EVALUATE ALTERNATIVE MAINTENANCE STRATEGIES FOR TREATMENT OF RECENTLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC) WITH BRCA MUTATION UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PIN67 BUDGET IMPACT ANALYSIS OF THE IMPLEMENTATION OF A PRESURGICAL WARMING PROTOCOL TO EFFECTIVELY MANAGE SURGICAL PATIENT NORMOTHERMIA

    Nov 1, 2019, 00:00

  • Copyright/Subscription

    Nov 1, 2019, 00:00

  • PNS8 IDENTIFYING MECHANISMS IN PARTICIPANT RECRUITMENT IN THE DANSIH EQ-5D-5L VALUATION STUDY

    Nov 1, 2019, 00:00

  • PNS233 ECONOMIC MODEL AND METHODOLOGIES EMPLOYED IN RECENT NICE SINGLE TECHNOLOGY APPRAISAL SUBMISSIONS

    Nov 1, 2019, 00:00

  • PRS44 CHARACTERISTICS OF MEDICARE ADVANTAGE BENEFICIARIES INITIATING LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA) USING DRY POWDER OR SOFT MIST INHALERS

    Nov 1, 2019, 00:00

  • PNS180 MONITORING OF DRG-BASED PAYMENT FOR IN-PATIENT AND DAY CARE IN RUSSIAN HOSPITALS IN 2016-2018

    Nov 1, 2019, 00:00

  • PCN133 A SYSTEMATIC LITERATURE REVIEW OF THE ECONOMIC BURDEN OF NEWLY DIAGNOSED MULTIPLE MYELOMA

    Nov 1, 2019, 00:00

  • PNS335 USING MACHINE LEARNING FOR EFFICIENCY IMPROVEMENTS IN SYSTEMATIC LITERATURE REVIEWS OF CLINICAL EFFICACY AND SAFETY

    Nov 1, 2019, 00:00

  • PDB64 COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE

    Nov 1, 2019, 00:00

  • PDG20 GLOBAL COMPARISON AND META-ANALYSIS OF INCREMENTAL COST-EFFECTIVENESS (ICER) FOR NEW CANCER DRUGS

    Nov 1, 2019, 00:00

  • PNS17 ASSESSING TECHNOLOGIES THAT ARE EFFECTIVE BUT NOT COST-EFFECTIVE AT ZERO PRICE: AN ALTERNATIVE FRAMEWORK

    Nov 1, 2019, 00:00

  • PDG6 A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS (NMA) OF CRISABOROLE 2% OINTMENT FOR THE TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS (AD)

    Nov 1, 2019, 00:00

  • PNS376 EQUIVALENCE OF ONLINE METHODS TO ASSESS CONTENT VALIDITY

    Nov 1, 2019, 00:00

  • PND85 EFFICACY AND SAFETY OF ABOBOTULINUMTOXINA IN ADULTS WITH UPPER LIMB SPASTICITY AFTER STROKE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN363 IMPACT OF OUTCOMES ON IQWIGS OVERALL BENEFIT RATING

    Nov 1, 2019, 00:00

  • PCN391 RISK-SHARING AGREEMENTS FOR ONCOLOGY DRUGS IN SWEDEN – THE NEW STANDARD FOR ACCESS?

    Nov 1, 2019, 00:00

  • PCV15 POTENTIAL IMPACT OF PROLONGED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR IN 'REAL WORLD' STABLE PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION VERSUS RANDOMIZED CONTROLLED TRIAL POPULATIONS

    Nov 1, 2019, 00:00

  • PCN523 INCIDENCE AND COST OF NON-CERVICAL HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED CANCER IN KOREA

    Nov 1, 2019, 00:00

  • PRO57 COST MINIMIZATION ANALYSIS OF EMICIZUMAB IN THE PROPHYLAXIS OF INHIBITOR-NEGATIVE PATIENTS WITH HEMOPHILIA A IN TURKEY

    Nov 1, 2019, 00:00

  • PMH7 LEVERAGING INNOVATIVE DIGITAL TECHNOLOGY: A NOVEL APPROACH TO SERVICE OPTIMISATION

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PRO33 IMPACT ON PRODUCTIVITY ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR HEMOPHILIA A WITH INHIBITORS IN COLOMBIA

    Nov 1, 2019, 00:00

  • PCN319 CONTEMPORARY EVIDENCE ON GLOBAL ECONOMIC BURDEN OF FRONTLINE CARE FOR PERIPHERAL T-CELL LYMPHOMA

    Nov 1, 2019, 00:00

  • PIN39 WHEN A PROBIOTIC-BASED SANITIZING METHOD MAY HALVE HEALTHCARE-ASSOCIATED INFECTIONS AND REDUCE ASSOCIATED COSTS

    Nov 1, 2019, 00:00

  • PCN215 COST COMPARISON OF LENALIDOMIDE BASED TRIPLE COMBINATION THERAPIES FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00

  • PSY52 PATIENT-REPORTED OUTCOME MEASURES IN ATOPIC DERMATITIS AND CHRONIC HAND ECZEMA IN ADULTS

    Nov 1, 2019, 00:00

  • PCN120 UTILIZATION AND EXPENDITURE OF COLORECTAL CANCER DRUGS IN THE MEDICAID PROGRAM FROM 1996 TO 2017

    Nov 1, 2019, 00:00

  • PCV150 DO WEATHER CHANGES AFFECT THE RISK OF STROKE? AN ANALYSIS USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCN192 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION IN GREECE

    Nov 1, 2019, 00:00

  • PNS60 CAN WE APPLY NICE COST-EFFECTIVENESS TO FRENCH EFFICIENCY OPTIONS: A COMPARISON OF SEVEN NICE AND HAS BASECASE COST-EFFECTIVENESS SCENARIOS

    Nov 1, 2019, 00:00

  • PCN262 ESTIMATION OF THE NUMBER OF PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA IN PORTUGAL

    Nov 1, 2019, 00:00

  • TP4 USE OF EPISODIC THERAPY IN MODERATE/SEVERE HEMOPHILIA A PATIENTS ACROSS THE EU5

    Nov 1, 2019, 00:00

  • PBI76 EVOLUTION OF INTERVENTIONAL TRIALS FOR GENE THERAPIES

    Nov 1, 2019, 00:00

  • PNS400 TREND IN STUDIES ON PATIENT REPORTED OUTCOMES

    Nov 1, 2019, 00:00

  • PRO8 EFFICACY OF CFTR MODULATORS AGAINST PULMONARY EXACERBATION IN CYSTIC FIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PSY9 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PDB51 PREVENTION AS A PUBLIC HEALTH MEASURE: LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF A POPULATION-BASED IODINE DEFICIENCY DISEASES PREVENTION PROGRAM

    Nov 1, 2019, 00:00

  • PCV128 DEVELOPING AN EQ-5D-5L VALUE SET USING HEART DISEASE PATIENT'S PREFERENCES

    Nov 1, 2019, 00:00

  • PRO160 COST ESTIMATION OF IMMUNOGLOBULIN RESCUE IN HOSPITALIZED PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): ANALYSIS OF A BRAZILIAN PRIVATE HEALTHCARE SYSTEM DATABASE

    Nov 1, 2019, 00:00

  • PCN300 CERVICAL CANCER PREVENTION IN INDONESIA: AN UPDATED CLINICAL IMPACT, COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PRO37 HEALTHCARE RESOURCE USE IN CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD STUDY

    Nov 1, 2019, 00:00

  • PDB101 PATTERNS OF ADHERENCE, PERSISTENCE, AND SWITCHING AMONG AUSTRALIANS PRESCRIBED DIPEPTIDYL PEPTIDASE-4 INHIBITORS

    Nov 1, 2019, 00:00

  • PNS82 HOW TO DEAL WITH CONTRADICTORY COST-EFFECTIVENESS OF THERAPEUTICALLY SIMILAR MEDICINES?

    Nov 1, 2019, 00:00

  • PCN190 COST–BENEFIT ANALYSIS OF INTERVENTIONS MADE BY PHARMACISTS IN CHEMOTHERAPY PREPARATION OF A REFERRAL HOSPITAL IN IRAN

    Nov 1, 2019, 00:00

  • PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

    Nov 1, 2019, 00:00

  • PCN194 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS240 POTENTIAL INFLUENCE OF HTA ON PRICE OUTCOMES OF NON-ORPHAN PHARMACEUTICALS IN THE GERMAN AMNOG PROCESS

    Nov 1, 2019, 00:00

  • Neurological Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PSU24 COMPARATIVE SAFETY OF SLEEVE GASTRECTOMY VS. ROUX-EN-Y: A RETROSPECTIVE COHORT ANALYSIS

    Nov 1, 2019, 00:00

  • PNS294 REVIEW OF ANALYTICAL METHODS FOR ANALYSIS OF PATIENT REPORTED OUTCOME (PRO) DATA IN THE PRESENCE OF CENSORING DUE TO DEATH

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PSY38 MARGINAL STRUCTURAL MODEL FOR STUDYING THE CAUSAL EFFECT BETWEEN VASO-OCCLUSIVE CRISES AND OCCURENCE OF DEATH OR COMPLICATIONS IN THE SICKLE-CELL DISEASE PATIENTS

    Nov 1, 2019, 00:00

  • PMU35 QUANTIFYING THE LOST MARKET SIZE OPPORTUNITY OF A TNF-INHIBITOR DUE TO DELAY IN TIME FROM PRIMARY TO SECONDARY INDICATION APPROVAL

    Nov 1, 2019, 00:00

  • PMH50 THE LONGITUDINAL VALIDITY OF THE CHU9D - EVIDENCE FROM A MENTAL HEALTH TRIAL

    Nov 1, 2019, 00:00

  • PCN28 METHOD TO ESTIMATE IMPACT OF PROGNOSTIC FACTORS ON SURVIVAL OUTCOMES USING MAXIMUM LIKELIHOOD ESTIMATION

    Nov 1, 2019, 00:00

  • PIN110 HEALTH AND ECONOMIC IMPACT OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE SEROTYPES IN ADULTS 65 YEARS AND OLDER IN 5 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PNS383 HEALTH-RELATED QUALITY OF LIFE IN ROMANIA: CROSS-SECTIONAL STUDIES USING EQ-5D-3L AND EQ-5D-5L

    Nov 1, 2019, 00:00

  • PND78 MULTIPLE SCLEROSIS IN PUERTO RICO: AN ANALYSIS OF DEMOGRAPHICS AND TREATMENT MODALITIES BY GEOGRAPHICAL REGION

    Nov 1, 2019, 00:00

  • RARE Public Health

    Nov 1, 2019, 00:00

  • PCN270 AVAILABILITY OF EARLY PREVENTION AND TARGETED THERAPY FOR BRCA-ASSOSIATED PATIENTS WITH BREAST AND/OR OVARIAN CANCER

    Nov 1, 2019, 00:00

  • PCN168 ECONOMIC BURDEN OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A RETROSPECTIVE CLAIMS-BASED ANALYSIS

    Nov 1, 2019, 00:00

  • PMS39 NATIONWIDE ANNUAL HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE SHOULDER AND UPPER ARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PCN464 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF CANCER PATIENTS TREATED WITH IMMUNOTHERAPY: USE OF SOCIAL MEDIA IN FRENCH LANGUAGE TO EXPLORE RELEVANCE OF CONCEPTS COVERED BY CANCER GENERIC HRQOL MEASURES

    Nov 1, 2019, 00:00

  • PCN527 US HEALTHCARE DATABASES FOR HEALTH ECONOMIC MODELING IN PRECISION MEDICINE: AN ONCOLOGY-BASED COMPARATIVE LANDSCAPE ASSESSMENT

    Nov 1, 2019, 00:00

  • PBI73 ASSESSMENT OF THE FUTURE IMPACT OF BIOSIMILARS AND GENERICS FOR ULCERATIVE COLITIS IN THE US EUROPE

    Nov 1, 2019, 00:00

  • CE4 COMPARISON OF NETWORK META-ANALYSIS (NMA) USING THE BAYESIAN AND FREQUENTIST APPROACH: CONCRETE EXAMPLE ON THE BASIS OF A PUBLISHED NMA IN RELAPSING REMITTING MULTIPLE SCLEROSIS AND PLAQUE PSORIASIS

    Nov 1, 2019, 00:00

  • PCN489 REAL WORLD MULTI-COUNTRY RETROSPECTIVE STUDY OF TREATMENT TRAVEL TIME AND WORK PRODUCTIVITY BURDEN AMONG HER2- NEGATIVE ADVANCED BREAST CANCER PATIENTS WITH A BRCA1/2 MUTATION

    Nov 1, 2019, 00:00

  • PMU72 ATTRIBUTES OF DISSATISFACTION OF HEALTH INSURANCE COVERAGE IN PATIENTS VISITED PUBLIC AND PRIVATE DENTAL HEALTHCARE CENTERS

    Nov 1, 2019, 00:00

  • PGI7 THE CLINICAL IMPACT OF THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE ─ A CRITICAL LITERATURE REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PSY46 WORK PRODUCTIVITY LOSS IN PATIENTS WITH INFLAMMATORY ARTHRITIS

    Nov 1, 2019, 00:00

  • PMD31 PERFORMANCE-BASED RISK SHARING AGREEMENTS: DO PAYERS CONSIDER MEDICINES AND MEDICAL DEVICES DIFFERENTLY?

    Nov 1, 2019, 00:00

  • PMS64 ASSESSING THE QUALITY OF BIOLOGIC SWITCH DECISIONS IN PSORIATIC ARTHRITIS: VALIDATION OF PASQAL - AN OUTCOMES MEASUREMENT TOOL

    Nov 1, 2019, 00:00

  • PDG61 CANCER DRUGS SHORTAGES IN ROMANIA: MAGNITUDE, CAUSES AND SOLUTIONS

    Nov 1, 2019, 00:00

  • PDB103 HUMANISTIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PUK14 COST-EFFECTIVENESS OF CONVECTIVE WATER VAPOR ENERGY THERAPY COMPARED TO PROSTATIC URETHRAL LIFT FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    Nov 1, 2019, 00:00

  • PNS277 THE ROLE OF EARLY VALUE FRAMEWORK IN A SUCCESSFUL REIMBURSEMENT JOURNEY

    Nov 1, 2019, 00:00

  • PCN156 COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR PREVIOUSLY UNTREATED ITALIAN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA

    Nov 1, 2019, 00:00

  • PUK13 COST-EFFECTIVENESS OF INTRODUCING A DIETARY INTERVENTION FOR RENAL TRANSPLANT RECIPIENTS

    Nov 1, 2019, 00:00

  • PCV144 ANTITHROMBOTIC PRESCRIBING IN A SOUTH AFRICAN PRIVATE HEALTHCARE SETTING, WITH THE FOCUS ON RIVAROXABAN

    Nov 1, 2019, 00:00

  • PCN310 "FREE” VS "CONTROLLED” PRICING SYSTEM: A EUROPEAN ASSESSMENT OF THE DISPARITIES IN ACCESS TO ONCOLOGY DRUGS

    Nov 1, 2019, 00:00

  • PIH15 EXTERNAL VALIDATION OF THE EX-ANTE BUDGET IMPACT ANALYSIS FOR PALIVIZUMAB

    Nov 1, 2019, 00:00

  • PIN96 EPIDEMIOLOGICAL AND ECONOMIC IMPACTS OF POTENTIAL HCV SCREENING STRATEGIES FOR THE NEXT 5 YEARS IN FRANCE

    Nov 1, 2019, 00:00

  • PCV62 ECONOMIC EVALUATION AND NETWORK META-ANALYSIS OF NON-STATIN THERAPY AMONG STATIN-TREATED PATIENTS IN THAILAND

    Nov 1, 2019, 00:00

  • Surgery - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PDB8 COMPARATIVE EFFECTIVENESS OF LIRAGLUTIDE AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN: A POPULATION-BASED COHORT STUDY

    Nov 1, 2019, 00:00

  • PNS188 ANALYSIS OF MARKET ACCESS AGREEMENTS IN TURKEY

    Nov 1, 2019, 00:00

  • PCN257 CERVICAL CANCER INCIDENCE IN A POPULATION OF 41,202 WOMEN SCREENED BY CONVENTIONAL CYTOLOGY AT A SINGLE PRIVATE LABORATORY OF SOUTHEAST BRAZIL

    Nov 1, 2019, 00:00

  • ND2 THE IMPACT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS ON WORK-RELATED OUTCOMES: A MIXED METHODS APPROACH

    Nov 1, 2019, 00:00

  • PRO43 BURDEN OF ILLNESS AMONG PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS

    Nov 1, 2019, 00:00

  • PRO31 MEDICAL INNOVATION ASSESSMENT AND ECONOMIC BURDEN OF DISEASES ON THE EXAMPLE OF RARE AND COMMON DISEASES IN POLAND

    Nov 1, 2019, 00:00

  • Drugs Information Systems

    Nov 1, 2019, 00:00

  • PCN292 CURRENT AND FUTURE EU5 PAYER LANDSCAPE FOR ONCOLOGY SOMATIC MUTATION PANELS

    Nov 1, 2019, 00:00

  • PCN404 HOW DO NEW ONCOLOGY VALUE ASSESSMENT FRAMEWORKS COMPARE TO THE QALY?

    Nov 1, 2019, 00:00

  • PMU16 SOCIETAL DISEASE SEVERITY PREFERENCES WHEN VALUING AND PRIORITIZING HEALTHCARE INTERVENTIONS.

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIT4 PATIENT CHARACTERISTICS AND HEALTHCARE UTILIZATION FOLLOWING COMMINUTED GUSTILO-ANDERSON TYPE III FRACTURES

    Nov 1, 2019, 00:00

  • PGI35 THE CLINICAL AND ECONOMIC IMPACT OF TDM (THERAPEUTIC DRUG MONITORING) ON CROHN DISEASE MANAGEMENT IN ITALY

    Nov 1, 2019, 00:00

  • PCV138 CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE PERIPHERAL ARTERY DISEASE QUALITY OF LIFE (PADQOL) QUESTIONNAIRE INTO HUNGARIAN: PILOTING RESULTS

    Nov 1, 2019, 00:00

  • PCN451 MODELING THE SURVIVAL BENEFIT OF IMMUNO-ONCOLOGIC THERAPY: A REVIEW OF METHODS USED IN NICE SINGLE TECHNOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PMU65 PRICE ANALYSIS OF NEW MEDICINAL PRODUCTS REIMBURSED IN ITALY AND GERMANY

    Nov 1, 2019, 00:00

  • PRO116 UNDERSTANDING THE ROLE OF REAL-WORLD EVIDENCE IN HEALTH TECHNOLOGY ASSESSMENT FOR ORPHAN DRUGS

    Nov 1, 2019, 00:00

  • PMH5 PATIENTS MAY BE CONCERNED WITH THE CONSEQUENCES OF THEIR ANSWERS WHEN REPORTING ON SYMPTOMS OF DEPRESSION

    Nov 1, 2019, 00:00

  • PNS54 FACIAL DRUG PRICES REGULATION BETWEEN 2011 AND 2018 IN FRANCE

    Nov 1, 2019, 00:00

  • PCN130 COST OF ILLNESS ANALYSIS: DRUG THERAPY OF PATIENTS WITH MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS IN MOSCOW

    Nov 1, 2019, 00:00

  • PNS114 IMPROVING THE TRANSPARENCY OF MARKETING AUTHORISATION DECISIONS: TOWARDS A FRAMEWORK FOR MANAGING UNCERTAINTIES

    Nov 1, 2019, 00:00

  • PIN26 ESTIMATING THE INVASIVE CANDIDIASIS COST-OF-CARE IN INTENSIVE CARE UNITS IN GREECE (HELICAS)

    Nov 1, 2019, 00:00

  • PMU19 RARE DISEASES AND THE COST FOR SOCIAL SECURITY SYSTEM: ESTIMATING THE SOCIO-ECONOMIC BURDEN IN ITALY

    Nov 1, 2019, 00:00

  • PIH45 UPTAKE OF ANTENATAL CARE SERVICES AMONG HIV POSITIVE WOMEN ATTENDING AN URBAN HIV CLINIC IN UGANDA

    Nov 1, 2019, 00:00

  • PNS22 USING TWITTER TO HARVEST DATA FROM SCIENTIFIC CONFERENCES:A PROOF OF CONCEPT OF A NEW APPROACH TO RETRIEVE CLINICAL TRIAL RESULTS

    Nov 1, 2019, 00:00

  • PNS408 HOW IS THE ENGLISH NHS PRESCRIPTION DRUGS BUDGET SPENT

    Nov 1, 2019, 00:00

  • PIH59 KNOWLEDGE OF HUMAN PAPILLOMAVIRUSAMONG WOMEN LIVINGIN SOMOGY AND BARANYA COUNTIES, HUNGARY

    Nov 1, 2019, 00:00

  • PCN126 REAL-WORLD TREATMENT SEQUENCING OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): WHAT ARE THE HEALTH ECONOMIC IMPLICATIONS?

    Nov 1, 2019, 00:00

  • PCN274 CLINICAL FACTORS ASSOCIATED WITH ADHERENCE TO THE SECONDARY SCREENING FOR COLORECTAL CANCER ACCORDING TO AGE IN KOREAN NATIONAL CANCER SCREENING PROGRAM

    Nov 1, 2019, 00:00

  • PCN420 NEW METHODOLOGIES IN PARAMETRIC NETWORK META-ANALYSIS: ACCOUNTING FOR POPULATION AGE DIFFERENCES BETWEEN TRIALS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PCN315 USE OF NOVEL HORMONAL AGENTS IN THE MONTH BEFORE DYING IN MEN DYING OF PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PRO60 PREVALENCE OF SANFILIPPO SYNDROME AND SUB-TYPES IN MAJOR GEOGRAPHICAL REGIONS

    Nov 1, 2019, 00:00

  • PND100 REFINEMENT OF THE TREATMENT PREFERENCE QUESTIONNAIRE IN ADULTS WITH PARKINSON'S DISEASE AND OFF-EPISODES

    Nov 1, 2019, 00:00

  • PNS303 BAYESIAN ESTIMATION OF THE TRANSITION PROBABILITY MATRIX IN MARKOV MODELLING WITH INFORMATIVE PRIOR: AN EXAMPLE FROM THE ANALYSIS OF THE TREATMENT OF PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA WITH CARIPRAZINE

    Nov 1, 2019, 00:00

  • PSU17 ECONOMIC ANALYSIS OF SUGAMMADEX FOR REVERSAL OF NEUROMUSCULAR BLOCKADE IN LAPAROSCOPIC SURGERY IN CHINA

    Nov 1, 2019, 00:00

  • PSU38 COST-EFFECTIVE ANALYSIS OF THREE METHODS OF SURGICAL-SITE INFECTION SURVEILLANCE: LESS IS MORE

    Nov 1, 2019, 00:00

  • PMH8 PSYCHOLOGICAL ASPECTS OF GENETIC COUNSELING IN RARE GENETIC CNS DISORDERS - SHOULD REGULATORS BE MORE INVOLVED?

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS?

    Nov 1, 2019, 00:00

  • PCN134 SOCIO-ECONOMIC COSTS OF BREAST CANCER: AN ITALIAN ANALYSIS

    Nov 1, 2019, 00:00

  • PCN329 TREATMENT PATTERNS IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PATIENTS IN SPAIN.

    Nov 1, 2019, 00:00

  • PCN476 THE PATIENT JOURNEY WITH METASTATIC PROSTATE CANCER: A PILOT QUALITATIVE STUDY FROM GREECE

    Nov 1, 2019, 00:00

  • PCN202 LIQUID BIOPSY FOR EGFR+ PATIENTS IN ADVANCED NSCLC: THE IMPACT OF DIFFERENT STRATEGIES

    Nov 1, 2019, 00:00

  • PCV133 HETEROGENEITY IN PREFERENCES FOR ANTI-COAGULANT USE IN ATRIAL FIBRILLATION: A LATENT CLASS ANALYSIS

    Nov 1, 2019, 00:00

  • Multiple Diseases - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PND110 SYMPTOM SEVERITY IN MULTIPLE SCLEROSIS FROM THE PATIENT'S PERSPECTIVE: REVISITING THE PSYCHOMETRIC PROPERTIES OF THE SYMPTOMSCREEN QUESTIONNAIRE (PERCEPTIONS-MS STUDY)

    Nov 1, 2019, 00:00

  • PCV84 REHOSPITALIZATION DUE TO SUBSEQUENT CARDIOVASCULAR EVENTS IN SECONDARY PREVENTION PATIENTS TREATED WITH LIPID LOWERING THERAPIES IN ITALY

    Nov 1, 2019, 00:00

  • PGI11 A BUDGET IMPACT MODEL FOR MEDICATION REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE PATIENTS TREATED WITH LAPAROSCOPIC NISSEN FUNDOPLICATION OR MAGNETIC SPHINCTER AUGMENTATION: AN ITALIAN PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS15 COVARIATE ADJUSTMENT IN INDIRECT TREATMENT COMPARISON (ITC): HOW TO BLEND THE USEFUL WITH THE AGREEABLE

    Nov 1, 2019, 00:00

  • PMD18 A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF C-REACTIVE PROTEIN POINT-OF-CARE TESTING TO GUIDE ANTIBIOTIC PRESCRIBING FOR RESPIRATORY TRACT INFECTIONS IN PRIMARY CARE SETTINGS IN IRELAND

    Nov 1, 2019, 00:00

  • PRO133 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND PULMONARY ARTERIAL HYPERTENSION (PAH) DISEASE SEVERITY: A REVIEW OF GRIPHON, SERAPHIN, COMPASS-2 AND EARLY TRIALS

    Nov 1, 2019, 00:00

  • PCV52 TRANSFERABILITY OF UK-BASED COST-EFFECTIVENESS MODEL TO HUNGARY, SWEDEN AND GERMANY: THE CASE OF MECHANICAL THROMBECTOMY BEYOND SIX HOURS FOLLOWING ADVANCED-IMAGING (VERSUS MECHANICAL THROMBECTOMY WITHIN SIX HOURS FOLLOWING CT+CTA) IN ...

    Nov 1, 2019, 00:00

  • PMU21 COST-UTILITY ANALYSES OF INTERVENTIONS FOR INFORMAL CAREGIVERS: A SYSTEMATIC AND CRITICAL REVIEW

    Nov 1, 2019, 00:00

  • PCN483 CONFIRMING THE PSYCHOMETRIC PERFORMANCE OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY–MELANOMA (FACT-M) QUESTIONNAIRE IN PATIENTS WITH MERKEL CELL CARCINOMA (MCC)

    Nov 1, 2019, 00:00

  • PCN204 COST-ESTIMATE OF ADDING NEOADJUVANT PERTUZUMAB FOR THE TREATMENT OF HER2+ BREAST CANCER IN AN INSTITUTION IN PORTUGAL

    Nov 1, 2019, 00:00

  • PRO95 FROM DRUG ACCESS TO VALUE BASED HEALTHCARE: INTEGRATED CARE PATHWAYS FOR HEMOPHILIA IN ITALY

    Nov 1, 2019, 00:00

  • PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN

    Nov 1, 2019, 00:00

  • PIN23 TREATING PATIENTS WITH DAAS ALLOWED TO SAVE 1 BILLION EUROS IN FRANCE - A BUDGET IMPACT MODEL FROM 2014 TO 2018

    Nov 1, 2019, 00:00

  • PNS4 A REVIEW OF PERFOS IN FDA AND EMA LABELLING CLAIMS (2009-2019)

    Nov 1, 2019, 00:00

  • PBI80 VARIATIONS IN TREATMENT PATTERNS OF PSORIASIS PATIENTS CURRENTLY EXPERIENCING 1ST LINE BIOLOGIC THERAPY IN EUROPE

    Nov 1, 2019, 00:00

  • PIH48 EVALUATING COVERAGE EXPANSION FOR NON-INVASIVE PRENATAL TESTING THROUGH A PERFORMANCE-BASED RISK SHARING AGREEMENT

    Nov 1, 2019, 00:00

  • PCN271 HODGKIN LYMPHOMA IN EUROPEAN COUNTRIES: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCN98 COST-COMPARISON ANALYSIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) AND TRANSARTERIAL CHEMOEMBOLISATION (TACE) IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PIN31 COST PER CYTOMEGALOVIRUS-ASSOCIATED DEATH AVERTED OF GANCICLOVIR AND VALGANCICLOVIR USE FOR PRE-EMPTIVE AND TREATMENT STRATEGIES IN ALLOGENEIC POSTTRANSPLANT RECIPIENTS

    Nov 1, 2019, 00:00

  • PND113 DESIGN OF THE INDIVIDUALISED PARKINSON'S DEPENDENT QUALITY OF LIFE (PARKINSON'SDQOL) AND THE PARKINSONS TREATMENT SATISFACTION QUESTIONNAIRE (PARKINSON'STSQ) USING TEMPLATES AND ITEM LIBRARIES FROM EXISTING DQOL AND TSQ MEASURES FOR ...

    Nov 1, 2019, 00:00

  • PRO126 A COMPOSITE PROGNOSTIC SCORE FOR TIME TO LOSS OF WALKING ABILITY IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

    Nov 1, 2019, 00:00

  • Injury Trauma - Patient-Centered Research

    Nov 1, 2019, 00:00

  • Infectious Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PRO144 HEALTH-RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES MEASURES IN IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • Mental Health - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PDG37 REAL-WORLD USE OF SELEXIPAG AND OTHER PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPIES: AN OBSERVATIONAL COHORT STUDY IN PATIENTS WITH PAH (EXPOSURE)

    Nov 1, 2019, 00:00

  • PNS96 TATTOO PREVALENCE, PERCEPTION AND REGRET IN US ADULTS: A 2017 CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PIN68 THE COST-EFFECTIVENESS OF HEPATITIS C VIRUS SCREENING AND TREATMENT STRATEGIES AMONG RECENTLY ARRIVED MIGRANTS FOR THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PDG57 DRUG PRICING PREDICTABILITY IN FRANCE: WHICH MANAGED ENTRY AGREEMENT SUITS THE BEST?

    Nov 1, 2019, 00:00

  • PDG84 REVIEW OF RELATIVE EFFECTIVENESS ASSESSMENTS (REAS) AT THE EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUNETHTA)

    Nov 1, 2019, 00:00

  • PND108 QUALITY OF LIFE OF PATIENTS AFTER ISCHAEMIC STROKE TREATED IN A PROVINCIAL HOSPITAL IN POLAND

    Nov 1, 2019, 00:00

  • PND34 ECONOMIC BURDEN OF PARKINSON'S DISEASE (PD) IN U.S.: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PDB30 THE INDIRECT COSTS OF DIABETES MELLITUS IN THE SLOVAK REPUBLIC

    Nov 1, 2019, 00:00

  • PMU5 ASSESSMENT OF ADVERSE DRUG REACTIONS IN PATIENTS WITH HEPATIC DISEASES AT THE DEPARTMENT OF GASTROENTEROLOGY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PRO136 PATIENT-REPORTED BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN THE USA AND UK MEASURED USING A DIGITAL APP

    Nov 1, 2019, 00:00

  • PCV68 ECONOMIC BURDEN OF ATHEROTROMBOTIC DISEASE IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00

  • PSY6 ABSENTEEISM IN ADULT PATIENTS WITH MODERATE-TO-SEVERE TREATED ATOPIC DERMATITIS IN PORTUGAL: AN ECONOMETRIC ANALYSIS

    Nov 1, 2019, 00:00

  • PSU7 THE DUTCH REFERENCE PRICE FOR INPATIENT DAYS SHOULD BE USED WITH SOME CAUTION

    Nov 1, 2019, 00:00

  • PDB81 HEALTHCARE RESOURCE USE ASSOCIATED WITH TYPE 2 DIABETES IN AFRICA, EURASIA, THE MIDDLE-EAST AND SOUTH-ASIA: RESULTS FROM THE 7TH WAVE OF THE INTERNATIONAL DIABETES MANAGEMENT PRACTICE STUDY (IDMPS)

    Nov 1, 2019, 00:00

  • PCV47 DOES THE COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN COMBINATION WITH STATIN THERAPY COMPARED TO STATIN ALONE DIFFER BETWEEN PRIMARY AND SECONDARY PREVENTION?

    Nov 1, 2019, 00:00

  • PMD22 COST-EFFECTIVENESS ANALYSIS OF SUCROSE OCTASULFATE (URGOSTART) DRESSING IN THE TREATMENT OF DIABETIC FOOT AND VENOUS LEG ULCERS

    Nov 1, 2019, 00:00

  • PMH38 IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH HYPONATREMIA IN PSYCHIATRIC PATIENTS: A CASE CONTROL STUDY

    Nov 1, 2019, 00:00

  • PCN372 METHODOLOGIES FOR ADJUSTMENT OF THE TRIAL OVERALL SURVIVAL FOR TREATMENT SWITCHING: A REVIEW OF NICE SUBMISSIONS

    Nov 1, 2019, 00:00

  • Cardiovascular Diabetes Disorder Studies

    Nov 1, 2019, 00:00

  • PDG13 CAN THE PURCHASING PERFORMANCE OF HEALTHCARE INSTITUTIONS BE ASSESSED VIA THE DATA DECLARED FOR REIMBURSEMENT?

    Nov 1, 2019, 00:00

  • Injury Trauma - Clinical Outcomes

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PUK20 ECONOMIC EVALUATION OF CILOSTAZOL IN COMPARISON WITH PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION IN IRAN

    Nov 1, 2019, 00:00

  • PNS287 PATIENT-CENTRICITY FOR PHARMACEUTICAL COMPANIES: NEW MODELS IN THE ERA OF CONNECTED HEALTH

    Nov 1, 2019, 00:00

  • PGI18 ASSESSMENT OF MEDICAL COSTS ASSOCIATED WITH CROHN'S DISEASE: A TARGETED LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • Neurological Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PCN307 IMPROVING PATIENT ACCESS TO PD-(L)1 THERAPIES IN CHINA: POLICY IMPLICATIONS FROM PREVIOUS NRDL NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PUK19 COST CONSEQUENCE ANALYSIS OF A REMOTE MONITORING PROGRAM FOR AUTOMATED PERITONEAL DYALISIS IN US

    Nov 1, 2019, 00:00

  • PNS19 THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE'S HIGHLY SPECIALISED TECHNOLOGIES PROCESS: A REVIEW OF PAST SUBMISSIONS AND RECOMMENDATIONS FOR THE FUTURE

    Nov 1, 2019, 00:00

  • PCN505 COSTS AND TREATMENT PATHWAYS OF OVARIAN CANCER CARE IN KAZAKHSTAN: RETROSPECTIVE ANALYSIS OF PATIENT-LEVEL ELECTRONIC HEALTH RECORDS

    Nov 1, 2019, 00:00

  • PNS395 PATIENT-REPORTED OUTCOME INSTRUMENTS IN ARABIC-SPEAKING POPULATIONS: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCV33 COST-EFFECTIVENESS OF WEARABLE CARDIOVERTER-DEFIBRILLATOR IN CHINA: A DECISION ANALYSIS

    Nov 1, 2019, 00:00

  • PIN135 MODELING HUMAN PAPILLOMAVIRUS TRANSMISSION FOR VACCINE EVALUATIONS: A PRELIMINARY AGENT-BASED MODEL

    Nov 1, 2019, 00:00

  • PNS265 MULTI-CRITERIA DECISION ANALYSIS AS A SUPPORTIVE TOOL FOR EFFICIENCY MEASURING IN HEALTH CARE

    Nov 1, 2019, 00:00

  • PCV82 ATHEROSCLEROSIS: BURDEN OF DISEASE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PBI86 INVESTIGATION ON THE CURRENT STATUS SURROUNDING BIOLOGICS AND THE IMPACT OF BIOSIMILARS USING JAPANESE REAL-WORLD DATA IN FY2017

    Nov 1, 2019, 00:00

  • PDG49 THE IMPACT OF FUTURE MEDICAL COSTS ON DUTCH PHARMACOECONOMIC ASSESSMENTS

    Nov 1, 2019, 00:00

  • PMS22 ANNUAL COST OF PATIENTS UNDERGOING A TOTAL KNEE REPLACEMENT IN FRANCE

    Nov 1, 2019, 00:00

  • PCN115 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2019, 00:00

  • PCN479 PATIENT-REPORTED SYMPTOM BURDEN OF CHRONIC GRAFT VERSUS HOST DISEASE: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCV60 BURDEN OF CARDIOVASCULAR DISEASE AND POTENTIAL IMPACT OF PCSK9I IN THE PREVENTION OF CARDIOVASCULAR EVENTS IN SWITZERLAND

    Nov 1, 2019, 00:00

  • PCN375 WHEN EARLY MODELS MAY BE TOO EARLY - PREDICTING SURVIVAL FROM INTERIM ANALYSES

    Nov 1, 2019, 00:00

  • PSU2 INDIRECT TREATMENT COMPARISON OF MINIMALLY INVASIVE GLAUCOMA SURGERGIES ON TOP OF PHACOEMULSIFICATION IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA

    Nov 1, 2019, 00:00

  • PNS299 THE INCREASING USE AND ACCEPTANCE OF ALTERNATIVE STATISTICAL APPROACHES TO INDIRECT COMPARISON IN THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSION PROCESS

    Nov 1, 2019, 00:00

  • PCN104 SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES OF CANCER IMMUNOTHERAPY MEDICINES

    Nov 1, 2019, 00:00

  • PCN362 DO ANTICANCER DRUGS ENTERING THE FRENCH MARKET PROVIDE SIGNIFICANT EVIDENCE OF THEIR CLINICAL EFFICACY?

    Nov 1, 2019, 00:00

  • Cancer - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PNS268 AGGREGATING MULTIPLE ENDPOINTS/PERFORMANCE INDICATORS TO CALCULATE A UNIDIMENSIONAL MEASUREMENT OF VALUE IN A COMPOSITE INDEX

    Nov 1, 2019, 00:00

  • PCN333 PREFERENCE ELICITATION FOR CANCER TREATMENT IN EUROPE: A SYSTEMATIC LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS

    Nov 1, 2019, 00:00

  • PNS107 PHARMACISTS KNOWLEDGE OF PROJECT MANAGEMENT PROPOSAL OR CHART

    Nov 1, 2019, 00:00

  • PNS363 VALUATION OF EQ-5D-Y HEALTH INDEX UISNG DISCRETE CHOICE EXPERIMENT (DCE) IN HONG KONG ADOLESCENT POPULATION: PILOT FEASIBILITY STUDY

    Nov 1, 2019, 00:00

  • PMU133 TRANSLATION AND CULTURAL ADAPTATION OF 15D QUALITY OF LIFE QUESTIONNAIRE FROM ENGLISH TO ROMANIAN LANGUAGE

    Nov 1, 2019, 00:00

  • PNS144 HOW THE RESULTS OF THE AMNOG EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY HAVE DEVELOPED OVER TIME

    Nov 1, 2019, 00:00

  • PCN163 SEQUENTIAL TREATMENT REGIMENS FOR ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A COST-EFFECTIVENESS ANALYSIS INCLUDING EXPERIENCE FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PIH31 BURDEN OF SHINGLES IN THE OVER 80'S IN THE UK

    Nov 1, 2019, 00:00

  • PSY14 A LITERATURE REVIEW TO IDENTIFY, CRITIQUE AND SELECT THE MOST SUITABLE ECONOMIC MODEL FOR USE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) UK HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS

    Nov 1, 2019, 00:00

  • PMH49 PERSONALIZED HEALTHCARE EPISODE IDENTIFICATION IN SCHIZOPHRENIA SPECTRUM DISORDER USING HEALTHCARE CONSUMPTION TRAJECTORIES

    Nov 1, 2019, 00:00

  • ON3 HOSPITAL COSTS BEFORE, DURING, AND AFTER DIAGNOSIS OF FIVE CANCER FORMS IN DENMARK DURING 2014

    Nov 1, 2019, 00:00

  • PMS28 HEALTHCARE SERVICE UTILISATION BY PATIENTS WITH CHRONIC LOW BACK PAIN - RESULTS FROM A GLOBAL 8,990 PATIENT SURVEY: CITIZENS' RESEARCH

    Nov 1, 2019, 00:00

  • PSY32 DELAY IN DIAGNOSIS OF PRIMARY LYMPHOEDEMA AND ITS IMPACT ON QUALITY OF LIFE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PCN40 A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS

    Nov 1, 2019, 00:00

  • PDB29 COST-EFFECTIVENESS ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PMH19 HEALTH CARE COSTS RELATED TO SCHIZOPHRENIA IN PATIENTS INITIATING ARIPIPRAZOLE LONG-ACTING INJECTABLE (LAI): RESULTS FROM THE DOMINO STUDY

    Nov 1, 2019, 00:00

  • Cost-Effectiveness Studies

    Nov 1, 2019, 00:00

  • PCN83 COST-UTILITY ANALYIS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES IN HEPATOCELLULAR CARCINOMA (HCC)

    Nov 1, 2019, 00:00

  • PDG85 TRUST THE EXPERTS? ACCEPTANCE OF EXPERT ELICITATION IN THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) SINGLE TECHNOLOGY APPRAISAL (STA) PROCESS

    Nov 1, 2019, 00:00

  • PMD30 MEDICAL DEVICES MANAGED ENTRY AGREEMENTS IN FRANCE: A RETROSPECTIVE ANALYSIS (2018-2019)

    Nov 1, 2019, 00:00

  • PCN502 RETROSPECTIVE GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] STUDY ON INITIAL TREATMENT OF BLADDER CARCINOMA (BCA) BY TRANSURETHRAL BLADDER RESECTION (TURB) - A COMPARATIVE ANALYSIS OF COSTS AND UROLOGICAL FOLLOW- ...

    Nov 1, 2019, 00:00

  • IN3 THE HEALTH SYSTEM BURDEN OF SELECTED VACCINE-PREVENTABLE ILLNESSES ON SECONDARY CARE IN ENGLAND: A FIVE-YEAR STUDY USING AN ADMINISTRATIVE HEALTHCARE DATASET

    Nov 1, 2019, 00:00

  • Clinical Outcomes Assessment Studies

    Nov 1, 2019, 00:00

  • PNS234 INTERNATIONAL HTA FRAMEWORKS AS ROADMAP TO REVISIT PHARMA ORGANISATION AND OPERATIONS

    Nov 1, 2019, 00:00

  • PMS54 FRACTURE LIAISON SERVICES

    Nov 1, 2019, 00:00

  • PDG51 OPTIMIZING CHINA BMI FUNDS THROUGH DRUG VOLUME-BASED PROCUREMENT: UNDERSTANDING THE RESULT, IMPACT AND CHALLENGES

    Nov 1, 2019, 00:00

  • PNS32 AUTOMATIC ABSTRACT SCREENING USING MACHINE LEARNING TECHNIQUES: ARE WE THERE YET AND HOW CAN WE MOVE FORWARD?

    Nov 1, 2019, 00:00

  • PCN44 COMPARATIVE EFFECTIVENESS OF EARLY VS. LATE USE OF SORAFENIB IN INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN

    Nov 1, 2019, 00:00

  • PCV113 MARKET ACCESS BARRIERS AND ADOPTION HURDLES FOR AI POWERED EHEALTH SOLUTIONS IN THE FIELD OF CARDIOLOGY

    Nov 1, 2019, 00:00

  • PDB27 ONCE-WEEKLY SEMAGLUTIDE COMPARED TO OTHER TWO GLP1-RAS AVAILABLE IN THE PUBLIC HEALTHCARE SYSTEM IN THE KINGDOM OF SAUDI ARABIA: A RELATIVE COST OF CONTROL ANALYSIS

    Nov 1, 2019, 00:00

  • PNS122 LONG-ACTING GENE THERAPIES: CURRENT DEVELOPMENT ACTIVITIES AND CHALLENGES FOR GERMANY'S STATUTORY HEALTH INSURANCE SYSTEM

    Nov 1, 2019, 00:00

  • Mental Health - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN398 THE IMPORTANCE OF DIFFERENT ENDPOINTS IN ONCOLOGY-RELATED HEALTH TECHNOLOGY ASSESSMENTS: RESULTS OF A REVIEW OF DECISIONS IN GERMANY

    Nov 1, 2019, 00:00

  • PIN9 CEFTAZIDIME-AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PNS224 SHOULD THE PATIENT VOICE HAVE AN ACTIVE ROLE IN HTA DECISION-MAKING? A PAG CONSENSUS ANALYSIS IN GREECE

    Nov 1, 2019, 00:00

  • PNS414 COMPARISON OF THREE LARGE REAL-WORLD DATABASES FROM THREE DIFFERENT COUNTRIES AND IMPLICATIONS FOR THEIR USE FOR RETROSPECTIVE STUDIES

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCN389 MATURE VERSUS REGISTRATION STUDIES OF IMMUNO-ONCOLOGY AGENTS: DOES VALUE IMPROVE WITH TIME?

    Nov 1, 2019, 00:00

  • PRO156 APPROACHES TO THE COLLECTION OF UTILITY VALUES FOR RARE DISEASES

    Nov 1, 2019, 00:00

  • PNS411 ASSESSMENT OF THE ACTIVITY OF PHARMACISTS IN ENSURING THE SAFE USE OF MEDICINES IN UKRAINE

    Nov 1, 2019, 00:00

  • PCN429 THE GENERATION OF SYNTHETIC CLINICAL TRIAL DATA

    Nov 1, 2019, 00:00

  • PRO77 INTERNATIONAL VARIATIONS IN THE APPRAISAL OF DRUGS FOR RARE DISEASES; WHAT ARE THE MAIN LESSONS?

    Nov 1, 2019, 00:00

  • PMU120 CRITICAL REVIEW OF VALIDATION STUDIES OF NATURAL LANGUAGE PROCESSING TECHNIQUES APPLIED TO INFORMATION FROM ELECTRONIC MEDICAL RECORDS DURING THE LAST 5 YEARS

    Nov 1, 2019, 00:00

  • PIN129 ANALYSIS OF THE RELATIONSHIP BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) EVALUATION AND REIMBURSED PRICE OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) COMBINATION DRUGS IN EU-3 (FRANCE, GERMANY, UNITED KINGDOM [UK])

    Nov 1, 2019, 00:00

  • Medical Devices - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PND105 HEALTHCARE RESOURCE UTILIZATION OF MIGRAINE IN BRAZIL: RESULTS FROM THE MY MIGRAINE VOICE SURVEY

    Nov 1, 2019, 00:00

  • PMD59 COST-EFFECTIVENESS EVALUATION OF PHACOEMULSIFICATION PLATFORMS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • Neurological Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS271 TESTING OF A QUESTIONNAIRE FOR ASSESSMENT OF RELATIVE WEIGHTS OF MEDICINES VALUE CRITERIA

    Nov 1, 2019, 00:00

  • PCV31 PATIENTS' PRODUCTIVITY LOSSES AND INFORMAL CARE COST RELATED TO ISCHEMIC STROKE IN RHONE AREA, FRANCE

    Nov 1, 2019, 00:00

  • PRO118 WHAT IS THE IMPACT OF ORPHAN DRUG RE-ASSESSMENTS IN GERMANY ON THEIR ADDITIONAL BENEFIT AND PRICE?

    Nov 1, 2019, 00:00

  • PIN28 COST EFFECTIVENESS ANALYSIS OF BACILLUS CALMETTE-GUÉRIN VACCINATION IN INDONESIA

    Nov 1, 2019, 00:00

  • PCN147 ENTRECTINIB IN NTRK TUMOR AGNOSTIC INDICATION COMPARED TO DIFFERENT STANDARD OF CARE IN VARIOUS TUMORS TYPES: A COST-EFFECTIVENESS ANALYSIS IN ITALIAN PATIENTS

    Nov 1, 2019, 00:00

  • PBI40 TENDER APPROACHES IN THE OFF-PATENT BIOLOGICAL MEDICINES MARKET: A EUROPEAN COMPARATIVE ANALYSIS

    Nov 1, 2019, 00:00

  • PCN461 CHARACTERIZATION OF THE CARE PATHWAYS OF PATIENTS WITH MERKEL CELL CARCINOMA IN FRANCE

    Nov 1, 2019, 00:00

  • PDB6 LONG-TERM ASSOCIATION OF OBSERVED VERSUS PREDICTED MICRO- AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS: EXTERNAL VALIDATION OF THE CORNERSTONE DIABETES SIMULATION MODEL (CDSM)

    Nov 1, 2019, 00:00

  • PMU150 ISHLT REGISTRY DATA AND COUNTRY REGISTRIES: COMPARISON OF REPORTED COUNTRY LUNG TRANSPLANT ACTIVITIES IN NORTH AMERICA AND EUROPEAN COUNTRIES IN 2016

    Nov 1, 2019, 00:00

  • PND40 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

    Nov 1, 2019, 00:00

  • PNS283 STATUS QUO OF CLAIMS DATA ANALYSES IN THE GERMAN AMNOG HTA PROCESS - DID QUALITY IMPROVE?

    Nov 1, 2019, 00:00

  • PCV146 CHARACTERIZATION OF PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)

    Nov 1, 2019, 00:00

  • PNS10 DEFINING CONFOUNDING BY INDICATION: RESOLVING THE GAP BETWEEN AN EPIDEMIOLOGIST AND ECONOMETRICIAN

    Nov 1, 2019, 00:00

  • PIH16 THE COST-EFFECTIVENESS OF STRATEGIES PREVENTING LATE-ONSET INFECTION IN PRETERM INFANTS

    Nov 1, 2019, 00:00

  • PMS14 FLARE QUESTIONNAIRE FOR RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND RECURRENCE IDENTIFICATION IN CLINICAL RESEARCH

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PNS167 QUANTITATIVE AND QUALITATIVE ANALYSIS OF DIFFERENCES IN AMNOG OUTCOMES BETWEEN IQWIG AND G-BA BETWEEN 2011-2018

    Nov 1, 2019, 00:00

  • PDB48 COST AND CAPACITY EFFECTS OF HEALTHYWEIGHTHUB @ VIRTUAL HOSPITAL 2.0 IN FINLAND

    Nov 1, 2019, 00:00

  • PIH37 ASSESSMENT OF PRECLINICAL MARKERS "MOBILITY LIMITATIONS” AND "COGNITIVE IMPAIRMENT” AMONG GERIATRIC INPATIENTS: EVIDENCE FROM THE CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PND129 BAD WEATHER CAUSES MIGRAINE? ASSOCIATION BETWEEN METEOROLOGICAL VARIABLES, HEADACHES AND MIGRAINE USING GERMAN CLAIMS DATA

    Nov 1, 2019, 00:00

  • PCV32 COST ANALYSIS OF REIMBURSED SPENDING ON ACE-INHIBITORS AND SARTANS IN BULGARIA

    Nov 1, 2019, 00:00

  • PMS24 HEALTH INSURANCE TREATMENT COST OF INJURIES TO THE ELBOW AND FOREARM IN HUNGARY: COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Nov 1, 2019, 00:00

  • PNS325 GAME THEORY IN THE HEALTHCARE LITERATURE:A SYSTEMATIC REVIEW FOCUSING ON NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PCV55 COST-EFFECTIVENESS OF WARFARIN CARE BUNDLES AND NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION IN THAILAND

    Nov 1, 2019, 00:00

  • Drugs Generics - Economic Evaluation

    Nov 1, 2019, 00:00

  • PIN97 ANTIMICROBIAL UTILIZATION AND INFECTION CAUSED BY GRAM-NEGATIVE BACTERIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES IN JAPAN: A MULTI-CENTRE CROSS-SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PRO15 ORPHAN DRUG METHODOLOGY CHALLENGES IN THE DANISH HTA PROCESS - MEDICINRAADET AND THE HURDLES TO SHOWING CLINICAL BENEFIT IN SMALL PATIENT POPULATIONS

    Nov 1, 2019, 00:00

  • PRO65 VARIABILITY IN AGE AT LOSS OF AMBULATION BY GENOTYPE AMONG BOYS WITH DUCHENNE MUSCULAR DYSTROPHY

    Nov 1, 2019, 00:00

  • PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIO ...

    Nov 1, 2019, 00:00

  • PRS38 PREVALENCE OF SEVERE ASTHMA IN PORTUGAL: RESULTS FROM A PHYSICIANS SURVEY

    Nov 1, 2019, 00:00

  • PIN119 NOVEL PRICING OF NEW ANTIMICROBIALS – HOW CAN WE PRICE TO REFLECT THE VALUE TO SOCIETY AND THE MANUFACTURER?

    Nov 1, 2019, 00:00

  • PNS151 THE ROLE OF REGULATORY GUIDANCE AND INFORMATION DISSEMINATION FOR BIOSIMILAR MEDICINES - THE PERSPECTIVE OF HEALTHCARE PROFESSIONALS AND INDUSTRY

    Nov 1, 2019, 00:00

  • PCN148 COST-UTILITY OF ENTRECTINIB VERSUS CRIZOTINIB IN ROS1+ NSCLC PATIENTS: AN AUC MODEL ADAPTED TO ITALIAN CLINICAL PRACTICE

    Nov 1, 2019, 00:00

  • PMH4 ASSESSMENT OF QUALITY OF LIFE AMONGST PATIENTS DEPRESCRIBED WITH BENZODIAZEPINES

    Nov 1, 2019, 00:00

  • PMS15 REAL-WORLD EFFECTIVENESS OF SECUKINUMAB FOR PSORIATIC ARTHRITIS PATIENTS: A MULTI-INSTITUTIONAL COHORT STUDY IN TAIWAN

    Nov 1, 2019, 00:00

  • PCN342 THE UPTAKE AND IMPACT OF THE EQ-5D-5L VALUE SET IN NICE TECHNOLOGY APPRAISALS WITHIN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS393 POPULATION NORMS WITH THE ICECAP-A AND ICECAP-O CAPABILITY MEASURES IN HUNGARY

    Nov 1, 2019, 00:00

  • PCN525 FIRST VALUE-BASED PRICE AGREEMENT IN FRANCE BASED ON PRM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • PDB99 UNDERSTANDING THE HUMANISTIC BURDEN AND PATIENT IMPACT IN NON-ALCOHOLIC STEATOHEPATITIS (NASH)

    Nov 1, 2019, 00:00

  • PRO54 ECONOMIC BURDEN OF CARE AND TREATMENT OPTIONS FOR PATIENTS WITH RETT SYNDROME: TWO SYSTEMATIC LITERATURE REVIEWS

    Nov 1, 2019, 00:00

  • PMS53 THE MOST COMMON REASONS FOR A MEDICAL VISIT AMONG PEOPLE PERFORMING CONDITIONING GYM WEIGHT TRAINING

    Nov 1, 2019, 00:00

  • PBI48 EQUALITY IN ACCESS TO DMARDS IN TURKEY

    Nov 1, 2019, 00:00

  • PSY27 AN EXAMINATION OF THE BURDEN OF SICKLE CELL DISEASE AMONG ADULTS IN ENGLAND

    Nov 1, 2019, 00:00

  • PND64 EPIDEMIOLOGY OF CHRONIC MIGRAINE: A REAL-WORLD STUDY IN PRIMARY CARE IN ITALY

    Nov 1, 2019, 00:00

  • Medical Devices - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PCN365 TITLE: REVIEW OF PUBLISHED EFFICIENCY OPINIONS OF THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP) IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PNS254 INCLUSION OF PRODUCTIVITY LOSSES IN HTA ASSESSMENTS IN FUNCTION OF WHO BEARS PRODUCTIVITY LOSSES IN THE REAL WORLD - A QUALITATIVE ASSESSMENT

    Nov 1, 2019, 00:00

  • PIN137 THE USE OF MULTI-YEAR AGE GROUPS IN VACCINATION MODELS BIAS THE RESULTS FOR VACCINATED INDIVIDUALS

    Nov 1, 2019, 00:00

  • PND96 COMPARISON OF PROPENSITY SCORE METHODS A CASE STUDY OF DIRECT ORAL ANTICOAGULANTS

    Nov 1, 2019, 00:00

  • PDB34 A PERSONALIZED SCREENING STRATEGY FOR DIABETIC RETINOPATHY: A COST-EFFECTIVENESS PERSPECTIVE

    Nov 1, 2019, 00:00

  • PRO137 PATIENT CHARACTERISTICS ASSOCIATED WITH GREATER HIDRADENITIS SUPPURATIVA SEVERITY AGREEMENT BETWEEN PATIENT AND CLINICIAN GLOBAL ASSESSMENTS

    Nov 1, 2019, 00:00

  • PIN79 ECONOMIC EVALUATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS IN CHINESE HOSPITALS

    Nov 1, 2019, 00:00

  • Personalized Precision Medicine - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PNS321 EASINESS AND RELIABILITY IN ESTIMATING PATIENT-LEVEL SURVIVAL DATA FROM KAPLAN-MEIER CURVES

    Nov 1, 2019, 00:00

  • PCV75 COST ANALYSIS OF COMPLICATIONS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN TURKEY

    Nov 1, 2019, 00:00

  • PCN13 HANNA – REAL-WORLD EVIDENCE FROM A GERMAN, PROSPECTIVE, NON-INTERVENTIONAL STUDY WITH NIVOLUMAB IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Nov 1, 2019, 00:00

  • PBI87 REAL-WORLD GOLIMUMAB EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS OR AXIAL SPONDYLARTHRITIS AND A TREATMENT FAILURE TO PREVIOUS TNFΑ INHIBITOR THERAPY

    Nov 1, 2019, 00:00

  • PRO6 TRANSLATION AND LINGUISTIC VALIDATION OF THE HEMOPHILIA QUALITY OF LIFE (HAEMO-QOL-A) QUESTIONNAIRE FOR USE WITH HEMOPHILIA PATIENTS

    Nov 1, 2019, 00:00

  • PPM3 GENOMIC SCREENING COSTS IN MODELLING: A PENALTY FOR INNOVATION?

    Nov 1, 2019, 00:00

  • PNS94 ESTIMATING MISSING BASELINE SERUM CREATININE FOR ACUTE KIDNEY INJURY DIAGNOSIS IN HOSPITALISED PATIENTS

    Nov 1, 2019, 00:00

  • PMU93 ASSESSING THE OUTCOMES FOR ORPHAN STATUS OR ACCELERATED ASSESSMENT EMA APPROVED MEDICINES: A COMPARISON OF HEALTH TECHNOLOGY ASSESSMENT IN DENMARK, FINLAND, NORWAY AND SWEDEN

    Nov 1, 2019, 00:00

  • PNS165 THE USE OF MANAGED ENTRY AGREEMENTS FOR ADVANCED THERAPIES IN EU5

    Nov 1, 2019, 00:00

  • PND91 APPLICATION OF BIG DATA IN RARE DISEASE MANAGEMENT: TREATMENT COST OF THERAPEUTIC PLASMA EXCHANGE VERSUS IMMUNOGLOBULINS IN AN INPATIENT SETTING

    Nov 1, 2019, 00:00

  • PRO155 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

    Nov 1, 2019, 00:00

  • PCN221 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN FOUR EUROPEAN COUNTRIES: FINDINGS FROM PREAMBLE

    Nov 1, 2019, 00:00

  • PMS66 A COMPARISON OF STATISTICAL METHODS USED IN TRIAL-BASED ECONOMIC EVALUATIONS; DOES IT MATTER WHICH METHOD IS USED?

    Nov 1, 2019, 00:00

  • PMD43 EFFICACY AND SAFETY OF MECHANICAL THROMBECTOMY IN PATIENTS WITH ISCHEMIC STROKE: AN UMBRELLA SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PIN3 SOFOSBUVIR/VELPATASVIR VS GLECAPREVIR/PIBRENTASVIR IN GENOTYPE 3 HEPATITIS C VIRUS INFECTED PATIENTS

    Nov 1, 2019, 00:00

  • PIN16 COST-EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM + METRONIDAZOLE AS A FIRST-LINE TREATMENT IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS IN TAIWAN

    Nov 1, 2019, 00:00

  • PBI2 COMPARISON OF A NEW FIBRIN SEALANT TO CURRENT HEMOSTASIS METHODS IN PERIPHERAL VASCULAR SURGERY: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00

  • PND95 PRODUCTIVITY LOSS COST IN MIGRAINE USING TWO DIFFERENT QUESTIONNAIRES: FINDINGS FROM THE BECOME STUDY FOR PORTUGAL

    Nov 1, 2019, 00:00

  • PNS281 DO SPANISH TPRS AFFECT THE NATIONAL PRICING AND REIMBURSEMENT OF DRUGS?

    Nov 1, 2019, 00:00

  • PIN29 PUBLIC HEALTH AND ECONOMIC IMPACT OF VACCINATION OF SENIORS WITH A HIGH DOSE TRIVALENT INFLUENZA VACCINE IN BRAZILIAN PRIVATE HEALTH CARE SYSTEM

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48 (current)
  • 49
  • 50
  • »